1
|
Drabczyńska A, Karcz T, Szymańska E, Köse M, Müller CE, Paskaleva M, Karolak-Wojciechowska J, Handzlik J, Yuzlenko O, Kieć-Kononowicz K. Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazepinopurinediones. Purinergic Signal 2013; 9:395-414. [PMID: 23543220 PMCID: PMC3757144 DOI: 10.1007/s11302-013-9358-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Accepted: 02/28/2013] [Indexed: 01/30/2023] Open
Abstract
Syntheses and biological activities of imidazo-, pyrimido- and diazepino[2,1-f]purinediones containing N-alkyl substituents (with straight, branched or unsaturated chains) are described. Tricyclic derivatives were synthesized by the cyclization of 8-bromo-substituted 7-(2-bromoethyl)-, 7-(3-chloropropyl)- or 7-(4-bromobutyl)-theophylline with primary amines under various conditions. Compound 22 with an ethenyl substituent was synthesized by dehydrohalogenation of 9-(2-bromoethyl)-1,3-dimethyltetrahydropyrimido[2,1-f]purinedione. The obtained derivatives (5-35) were initially evaluated for their affinity at rat A1 and A2A adenosine receptors (AR), showing moderate affinity for both adenosine receptor subtypes. The best ligands were diazepinopurinedione 28 (K i = 0.28 μM) with fivefold A2A selectivity and the non-selective A1/A2A AR ligand pyrimidopurinedione 35 (K i A1 = 0.28 μM and K i A2A = 0.30 μM). The compounds were also evaluated for their affinity at human A1, A2A, A2B and A3 ARs. All of the obtained compounds were docked to the A2A AR X-ray structure in complex with the xanthine-based, potent adenosine receptor antagonist-XAC. The likely interactions of imidazo-, pyrimido- and diazepino[2,1-f]purinediones with the residues forming the A2A binding pocket were discussed. Furthermore, the new compounds were tested in vivo as anticonvulsants in maximal electroshock, subcutaneous pentylenetetrazole (ScMet) and TOX tests in mice (i.p.). Pyrimidopurinediones showed anticonvulsant activity mainly in the ScMet test. The best derivative was compound 11, showing 100 % protection at a dose of 100 mg/kg without symptoms of neurotoxicity. Compounds 6, 7, 8 and 14 with short substituents showed neurotoxicity and caused death. In rat tests (p.o.), 9 was characterized by a high protection index (>13.3). AR affinity did not apparently correlate with the antiepileptic potency of the compounds.
Collapse
Affiliation(s)
- Anna Drabczyńska
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Tadeusz Karcz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Ewa Szymańska
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Meryem Köse
- PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany
| | - Christa E. Müller
- PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany
| | - Minka Paskaleva
- PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany
| | | | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Olga Yuzlenko
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
- Present Address: Department of Chemistry, City College of New York, City University of New York, 160 Convent Avenue, New York, NY 10031 USA
| | - Katarzyna Kieć-Kononowicz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| |
Collapse
|
2
|
Gütschow M, Schlenk M, Gäb J, Paskaleva M, Alnouri MW, Scolari S, Iqbal J, Müller CE. Benzothiazinones: A Novel Class of Adenosine Receptor Antagonists Structurally Unrelated to Xanthine and Adenine Derivatives. J Med Chem 2012; 55:3331-41. [DOI: 10.1021/jm300029s] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Michael Gütschow
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Miriam Schlenk
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Jürgen Gäb
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Minka Paskaleva
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Mohamad Wessam Alnouri
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Silvia Scolari
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Jamshed Iqbal
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| | - Christa E. Müller
- PharmaCenter
Bonn, University of Bonn, Pharmaceutical
Institute, Pharmaceutical Chemistry I, Bonn, Germany
| |
Collapse
|